Streetbeat News

CFIV

CF Acquisition Corp. IV

Open

10.58

Mkt cap

221M

Volume

441

High

10.58

P/E Ratio

529.00

52-wk high

11.01

Low

10.58

Div yield

N/A

52-wk low

9.99

CF Acquisition Corp. IV has announced its intention to liquidate, stating it will not make the next $150,000 monthly installment to its trust account due by November 28. The company will cease all operations except for the purpose of winding up, redeeming public shares, dissolving, and liquidating.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 9:35 pm

Several stocks are experiencing significant pre-market movements. Senti Biosciences, Tharimmune, TransMedics Group, GSE Systems, Unisys Corporation, Alteryx, Augmedix, Color Star Technology, CF Acquisition Corp. IV, and Tripadvisor reported gains due to various reasons such as strategic collaborations, licensing agreements, better-than-expected Q3 results, and strong FY23 revenue guidance. On the other hand, Ventyx Biosciences, Alto Ingredients, MSP Recovery, Coherus BioSciences, Ameresco, Aura Biosciences, Clover Health Investments, Trevena, Tenon Medical, and NanoString Technologies reported losses due to reasons such as disappointing trial results, mixed Q3 results, and weak quarterly sales.

Portfolio Pulse from Lisa Levin

November 07, 2023 | 1:28 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.